The Technical Analyst
Emerald Health [EMHTF]
Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Emerald Health Price, Forecast, Insider, Ratings, Fundamentals & Signals
55.17% $0.0405
America/New_York / 11 nov 2022 @ 15:42
| RATING 2022-11-14 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.327 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.327 | industry: PE 31.46 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0365 - 0.0445 ( +/- 9.88%) |
| ATR Model: 14 days |
Forecast:
01:40 - $0.0310
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0405 (55.17% ) |
| Volume | 1.051 mill |
| Avg. Vol. | 0.0892 mill |
| % of Avg. Vol | 1 177.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EMHTF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EMHTF
Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.
Latest Press Releases
2021-09-10 16:15:00 - Press Release
Emerald Health Therapeutics Announces Chief Financial Officer Transition
Vancouver, british columbia--(newsfile corp. - september 10, 2021) - emerald health therapeutics, inc. (cse: emh) (otcqx: emhtf) ("emerald") announced today that its chief financial officer, jenn hepburn, will be stepping down from her position at emerald, effective october 15, 2021, to pursue other interests. she will continue in her role until that time to help with transition-related activities."jenn's effort has been pivotal in the implementation of strong financial systems and controls, and in helping emerald...
2021-08-31 07:00:00 - Press Release
Emerald Health Therapeutics Reports 2021 Second Quarter Financial Results And Provides Corporate Update
Vancouver, british columbia--(newsfile corp. - august 31, 2021) - emerald health therapeutics, inc. (cse: emh) (otcqx: emhtf) ("emerald") has released its financial results for the three and six months ended june 30, 2021. full versions of emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on www.sedar.com."in the second quarter we started to see incremental progress in executing on our renewed business strategy, resulting in a 42% sequential quarterly...
2021-08-25 07:00:00 - Press Release
Emerald Health Therapeutics To Host 2021 Second Quarter Financial Results Conference Call On Tuesday, August 31, 2021 At 10:30 Am Et
Vancouver, british columbia--(newsfile corp. - august 25, 2021) - emerald health therapeutics, inc. (cse: emh) (otcqx: emhtf) ("emerald") today announced that it will report its financial results for the second quarter ended june 30, 2021, after the market close on monday, august 30, 2021. the company will host a conference call on tuesday, august 31, 2021, at 10:30 a.m. et.to access the audio broadcast, please dial (866) 652-5200, or via the internet at: https://services.choruscall.com/mediaframe/webcast.html?webcastid=baodjldgan archived version of the...
2021-08-10 07:00:00 - Press Release
Emerald Health Therapeutics Hires Vp Sales & Marketing
Vancouver, british columbia--(newsfile corp. - august 10, 2021) - emerald health therapeutics, inc. (cse: emh) (otcqx: emhtf) ("emerald") has appointed nick mosgrove as vp sales & marketing. mr. mosgrove has over 15 years of sales and marketing leadership experience in the canadian alcohol beverage and cannabis sectors.most recently mr. mosgrove was vp sales & marketing for terrascend canada. in this role he developed and implemented a commercial plan that resulted in 1500+ retail accounts across...
2021-08-06 19:24:00 - Press Release
Emerald Health Therapeutics Executive Chairman Avtar Dhillon Resigns
Vancouver, british columbia--(newsfile corp. - august 6, 2021) - emerald health therapeutics, inc. (cse: emh) (otcqx: emhtf) ("emerald") today announced that avtar dhillon, md, has resigned from his roles as director and executive chairman of emerald's board of directors for personal reasons effective immediately."we would like to thank dr. dhillon for his significant contributions to the building of emerald and wish him all the best in his future endeavors," said jim heppell, incoming chairman of...
Latest News
2022-11-11 08:36:58 - Proactive Investors
Skye Bioscience concludes merger with Emerald Health Therapeutics and unveils goals for 2022 and 2023
Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted in favor and the Supreme Court of British Columbia approved the transaction. As of the date of closing, Skye has entered into agreements to divest certain remaining cannabis assets and licenses, including the Quebec cannabis production facility.
2022-08-22 07:01:49 - Proactive Investors
Skye Bioscience says Emerald Health Therapeutics shareholders approve integration plan of arrangement; gets regulatory approval to begin first-in-human clinical study
Skye Bioscience Inc (OTCQB:SKYE) has announced that the shareholders of Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have approved the proposed plan of arrangement which will result in the integration of the two companies, and also revealed regulatory approval to begin its first-in-human Phase 1 clinical study. The pharma company said Emerald will now seek a final order from the Supreme Court of British Columbia to approve the arrangement.
2022-05-12 09:53:45 - Proactive Investors
Skye Bioscience signs agreement to merge with Emerald Health Therapeutics
Skye Bioscience Inc (OTCQB:SKYE) and Emerald Health Therapeutics Inc said they have entered into a definitive agreement that will see Skye acquiring Emerald in a share-for-share transaction. Under the proposed plan of arrangement, Skye will issue Emerald shareholders 1.95 shares of its shares in exchange for each Emerald share, resulting in current Skye stockholders owning approximately 54% of its common stock and former shareholders of Emerald owning approximately 46%.
2021-11-29 12:36:38 - Benzinga
Emerald Health Therapeutics Leaving 'Saturated' Cannabis Market, Will Focus On Pharmaceuticals
Emerald Health Therapeutics, Inc. (CSE:EMH) (OTCQX:EMHTF) announced Monday that it is getting out of the recreational and medical cannabis industry and pivoting to pharmaceutical development. The company also announced its president and CEO, Riaz Bandali has resigned.
2021-09-10 16:15:00 - Newsfile Corp
Emerald Health Therapeutics Announces Chief Financial Officer Transition
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") announced today that its Chief Financial Officer, Jenn Hepburn, will be stepping down from her position at Emerald, effective October 15, 2021, to pursue other interests. She will continue in her role until that time to help with transition-related activities."Jenn's effort has been pivotal in the implementation of strong financial systems and controls, and in helping Emerald...
2021-08-31 11:53:07 - Seeking Alpha
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q2 2021 Results - Earnings Call Transcript
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q2 2021 Results - Earnings Call Transcript
2021-08-31 07:00:00 - Newsfile Corp
Emerald Health Therapeutics Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the three and six months ended June 30, 2021. Full versions of Emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on www.sedar.com."In the second quarter we started to see incremental progress in executing on our renewed business strategy, resulting in a 42% sequential quarterly...
2021-08-25 07:00:00 - Newsfile Corp
Emerald Health Therapeutics to Host 2021 Second Quarter Financial Results Conference Call on Tuesday, August 31, 2021 at 10:30 AM ET
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it will report its financial results for the second quarter ended June 30, 2021, after the market close on Monday, August 30, 2021. The company will host a conference call on Tuesday, August 31, 2021, at 10:30 a.m. ET.To access the audio broadcast, please dial (866) 652-5200, or via the internet at: https://services.choruscall.com/mediaframe/webcast.html?webcastid=BaOdjlDgAn archived version of the...
2021-08-10 07:00:00 - Newsfile Corp
Emerald Health Therapeutics Hires VP Sales & Marketing
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has appointed Nick Mosgrove as VP Sales & Marketing. Mr. Mosgrove has over 15 years of sales and marketing leadership experience in the Canadian alcohol beverage and cannabis sectors.Most recently Mr. Mosgrove was VP Sales & Marketing for TerrAscend Canada. In this role he developed and implemented a commercial plan that resulted in 1500+ retail accounts across...
2021-08-06 19:24:00 - Newsfile Corp
Emerald Health Therapeutics Executive Chairman Avtar Dhillon Resigns
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that Avtar Dhillon, MD, has resigned from his roles as director and Executive Chairman of Emerald's board of directors for personal reasons effective immediately."We would like to thank Dr. Dhillon for his significant contributions to the building of Emerald and wish him all the best in his future endeavors," said Jim Heppell, incoming Chairman of...